ELVNEnliven Therapeutics, Inc.

$40.98+116% 1Y

The financials

Enliven Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 11, 2026, the same week as a year ago.

Enliven Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$37M−$29Mn/a
Net income−$32M−$25Mn/a
Diluted EPS−$0.49−$0.49n/a
On our screens:Most shorted stocks